Immunitybio is trading at $8.36 (-5.75%) in a sharp pullback from its prior close of $8.87 despite a lack of major company-specific news.
- No earnings releases, FDA actions, or significant deal announcements have been identified to explain the downward move.
- The decline appears independent of broader market sentiment, as the NASDAQ Composite is down a marginal 0.06%.
- The price action likely reflects profit-taking or position unwinding following a period of recent volatility.